# Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer

> **NCT02673814** · PHASE2 · WITHDRAWN · sponsor: **Peregrine Pharmaceuticals**

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** durvalumab
- **BIOLOGICAL:** bavituximab

## Key facts

- **NCT ID:** NCT02673814
- **Lead sponsor:** Peregrine Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-02
- **Primary completion:** 2017-04
- **Final completion:** 2018-04
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02673814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02673814, "Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02673814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*